重组全长恶性疟原虫环子孢子蛋白疫苗联合吡喃葡萄糖脂A-脂质体皂树皂苷21佐剂:1期疟疾攻击试验结果
该开放标签、剂量递增1期研究在健康疟疾未暴露成人中评估重组全长环子孢子蛋白疫苗(rCSP)联合GLA-LSQ佐剂的安全性、反应原性、抗体应答及同源控制性人疟疾感染后的疟原虫血症。结果显示无严重不良事件,但所有26名接受攻击的参与者均发生疟疾,试验方案未诱导保护性免疫。
要点
- rCSP/GLA-LSQ安全性良好,各组征集性和非征集性不良事件发生率相似。
- 所有26名完成控制性人疟疾攻击的参与者均发生疟疾。
- 疫苗剂量增加可诱导更高免疫球蛋白G滴度,但未达到既往RTS,S基准。
核心结论
- rCSP/GLA-LSQ安全性结果良好,但所测试方案未诱导保护性免疫。
- 进一步研究可评估佐剂或免疫程序调整是否能改善效力。
研究设计与样本
- 开放标签、剂量递增1期研究,在健康、疟疾未暴露成人中进行。
- rCSP/GLA-LSQ于第1、29、85天或第1、490天给药。
- 主要终点为安全性和反应原性;次要终点为抗体应答及同源控制性人疟疾感染后的恶性疟原虫血症。
主要发现
- 参与者分4组接受rCSP/GLA-LSQ:10 µg×3(n=20)、30 µg×3(n=10)、60 µg×3(n=10)或60 µg×2(n=9)。
- 10名参与者单独接受30 µg rCSP×3,另有6名感染对照。
- 参与者未发生严重不良事件,各组征集性和非征集性不良事件发生率相似。
- 所有26名在末次接种后28天接受控制性人疟疾感染的参与者均发生疟疾。
- 增加疫苗剂量可诱导更高免疫球蛋白G滴度,但未达到既往建立的RTS,S基准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Malaria is preventable yet causes >600 000 deaths annually. RTS,S, the first marketed malaria vaccine, has modest efficacy, but improvements are needed for eradication. METHODS: We conducted an open-label, dose escalation phase 1 study of a full-length recombinant circumsporozoite protein vaccine (rCSP) administered with adjuvant glucopyranosyl lipid A-liposome Quillaja saponaria 21 formulation (GLA-LSQ) on days 1, 29, and 85 or 1 and 490 to healthy, malaria-naive adults. The primary end points were safety and reactogenicity. The secondary end points were antibody responses and Plasmodium falciparum parasitemia after homologous controlled human malaria infection. RESULTS: Participants were enrolled into 4 groups receiving rCSP/GLA-LSQ: 10 µg × 3 (n = 20), 30 µg × 3 (n = 10), 60 µg × 3 (n = 10), or 60 µg × 2 (n = 9); 10 participants received 30 µg rCSP alone × 3, and there were 6 infectivity controls. Participants experienced no serious adverse events. Rates of solicited and unsolicited adverse events were similar among groups. All 26 participants who underwent controlled human malaria infection 28 days after final vaccinations developed malaria. Increasing vaccine doses induced higher immunoglobulin G titers but did not achieve previously established RTS,S benchmarks. CONCLUSIONS: rCSP/GLA-LSQ had favorable safety results. However, tested regimens did not induce protective immunity. Further investigation could assess whether adjuvant or schedule adjustments improve efficacy. CLINICAL TRIALS REGISTRATION: NCT03589794.
引用
- Friedman-Klabanoff DJ, Berry AA, Travassos MA, et al. Recombinant Full-length Plasmodium falciparum Circumsporozoite Protein-Based Vaccine Adjuvanted With Glucopyranosyl Lipid A-Liposome Quillaja saponaria 21: Results of Phase 1 Testing With Malaria Challenge. J Infect Dis. 2024. PMID: 38330357. doi:10.1093/infdis/jiae062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。